In Vivo summarizes the technologies of several recently founded companies: Avantium B.V., a joint venture of GSE Systems, Shell International Chemical, SmithKline Beecham, WR Grace & Co. and three Dutch universities, will employ high-speed experimentation and simulation technologies to speed product development in the chemical and pharmaceutical industries. Framingham Genomic Medicine will assemble, analyze and expand data from the Framingham Heart Study and make it available to pharmaceutical companies to aid in their drug discovery and development efforts. Ireland's HiberGen Ltd. will use SNaPIT, its proprietary SNP genotyping platform, to identify "disease genes" and conduct pharmacogenomic analysis in the development of individualized therapeutics and diagnostics. iMEDD Inc. will create therapeutic microdevices for delivering drugs directly to the part of the body where they are needed. Using a genomic based drug discovery platform licensed from Brown University, Nemogen Inc. will create pharmaceuticals for enhancing memory and learning. PointDX Inc. is developing integrated imaging analysis and reporting software which it claims will produce faster, cheaper, more accurate radiology reports than the current dictation or future voice recognition processes allow.